GILEAD SCIENCES, INC. — fact timeline

GILEAD SCIENCES, INC. entered into Eleventh Supplemental Indenture with Computershare Trust Company, National Association valued at $500,000,000 aggregate principal amount of the Company's 4.250% Senior Notes due 2028, $1,000,000,00 (effective 2026-05-20).

“On May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental Indenture (the “Eleventh Supplemental Indenture”) to the Indenture between the Parties, dated as of March 30, 2011 (the “Base Indenture”).”

GILEAD SCIENCES, INC. incurred senior notes of $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2028, $1,000,000,000 aggregate principa with Computershare Trust Company, National Association, as trustee at 4.250% per annum until May 20, 2028; 4.400% per annum until May 20, 2029; 4.600% maturing May 20, 2028; May 20, 2029; May 20, 2031; May 20, 2034.

“Supplemental Indenture On May 20, 2026, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into an Eleventh Supplemental Indenture (the “Eleventh Supplemental Indenture”) to the Indenture between the Parties, dated as of March 30, 2011 (the “Base Indenture”). The Eleventh Supplemental Indenture relates to the Company’s issuance of (a) $500,000,000 aggregate principal amount of the Company’s 4.250% Senior Notes due 2028 (the “2028 Notes”), (b) $1,000,000,000 aggregate principal amount of the Company’s 4.400% Senior Notes due 2029 (the “2029 Notes”), (c) $1,000,000,000 aggregate principal amount of the Company’s 4.600% Senior Notes due 2031 (the “2031 Notes”) and (d) $500,000,000 aggregate principal amount of the Company’s 4.900% Senior Notes due 2034 (the “2034 Notes” and, together with the 2028 Notes, the 202”

GILEAD SCIENCES, INC. reported first quarter 2026 results: revenue $7.0 billion, EPS $1.61. Guidance raised.

“in 2026, Gilead is well-positioned for sustained growth in the near and long term.” First Quarter 2026 Financial Results • Total first quarter 2026 revenues increased 4% to $7.0 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy), and Livdelzi® (seladelpar), partially offset by”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics at the 2026-04-30 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting a report on the risks of ESG and DEI executive compensation metrics. The proposal received the following votes: Votes For 7,262,421 Votes Against 1,022,330,186 Abstentions 5,579,470 Broker Non-Votes 95,008,389”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access at the 2026-04-30 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access. The proposal received the following votes: Votes For 134,042,210 Votes Against 886,986,584 Abstentions 14,143,283 Broker Non-Votes 95,008,389”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting an independent Board Chair policy at the 2026-04-30 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting an independent Board Chair policy. The proposal received the following votes: Votes For 280,044,780 Votes Against 752,716,225 Abstentions 2,411,072 Broker Non-Votes 95,008,389”

GILEAD SCIENCES, INC. shareholders approved Amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan at the 2026-04-30 meeting.

“The Company’s stockholders approved the amended and restated Gilead Sciences, Inc. 2022 Equity Incentive Plan. The proposal received the following votes: Vote For 970,290,586 Vote Against 62,501,433 Abstentions 2,380,058 Broker Non-Votes 95,008,389”

GILEAD SCIENCES, INC. shareholders approved Advisory approval of compensation of Named Executive Officers at the 2026-04-30 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: Votes For 954,325,805 Votes Against 77,503,947 Abstentions 3,342,325 Broker Non-Votes 95,008,389”

GILEAD SCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2026-04-30 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The proposal received the following votes: Votes For 1,046,350,569 Votes Against 82,831,295 Abstentions 998,602”

GILEAD SCIENCES, INC. shareholders approved Election of nine directors at the 2026-04-30 meeting.

“Name Votes For Votes Against Abstentions Broker Non-Votes Jacqueline K. Barton, Ph.D. 1,013,176,696 21,056,724 938,657 95,008,389 Jeffrey A. Bluestone, Ph.D. 1,017,337,149 16,873,041 961,887 95,008,389 Sandra J. Horning, M.D. 1,002,426,858 31,078,619 1,666,600 95,008,389 Kelly A. Kramer 995,947,854 38,240,224 983,999 95,008,389 Ted W. Love, M.D. 1,016,607,688 17,592,385 972,004 95,008,389 Harish Manwani 995,710,468 38,469,820 991,789 95,008,389 Daniel P. O’Day 980,597,212 50,179,985 4,394,880 95,008,389 Javier J. Rodriguez 1,019,197,783 15,002,200 972,094 95,008,389 Anthony Welters 992,619,897 40,842,646 1,709,534 95,008,389”

GILEAD SCIENCES, INC. entered into Merger Agreement with Arcellx, Inc. (effective 2026-02-22).

“On February 22, 2026, Gilead Sciences, Inc., a Delaware corporation (“ Parent ” or “ Gilead ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”), among Parent, Arcellx, Inc., a Delaware corporation (the “ Company ”), and Ravens Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”).”

GILEAD SCIENCES, INC.: Amended and restated bylaws to revise procedural and disclosure requirements for director nominations and stockholder proposals, reserve white proxy card, update provisions regarding adjournment and stockholder list under DGCL, clarify majority vote provisions, and add emergency condition provisions (effective 2025-07-30).

“On July 30, 2025 , the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) approved an amendment and restatement of the Company’s bylaws (the “Amended and Restated Bylaws”), effective as of such date, in order to: • revise the procedural and disclosure requirements for the nomination of directors and the submission of proposals for consideration at meetings of the stockholders under the advance notice provisions (other than proposals to be included in the Company’s proxy statement pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), including, without limitation, by: ◦ clarifying and enhancing the background information and disclosures required by or regarding proposing stockholders, proposed nominees and business, and other control persons or persons known to be acting in concert with a proposing stockholder, including with respect to certain plans or proposals of and any planned solicitation by such persons; ◦ clari”

Diane E. Wilfong was appointed as interim Corporate Controller and Chief Accounting Officer at GILEAD SCIENCES, INC..

“The Company’s Board of Directors has appointed Diane E. Wilfong as the Company’s interim Corporate Controller and Chief Accounting Officer, and designated her as the interim principal accounting officer, effective immediately.”

Sandra Patterson departed as Senior Vice President, Corporate Controller and Chief Accounting Officer at GILEAD SCIENCES, INC..

“Sandra Patterson, the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer and the Company’s principal accounting officer, has decided to leave the Company.”

Merdad V. Parsey resigned as Chief Medical Officer at GILEAD SCIENCES, INC..

“announced that its Chief Medical Officer, Merdad V. Parsey, M.D., Ph.D., will leave the Company.”

GILEAD SCIENCES, INC.: Adopted amendments to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the DGCL (effective 2024-05-08).

“the Board of Directors (the “Board”) of Gilead Sciences, Inc. (the “Company”) adopted amendments to the Company’s Restated Certificate of Incorporation (the “Amendment”) to reflect new Delaware law provisions regarding officer exculpation under Section 102(b)(7) of the Delaware General Corporation Law (the “DGCL”). On May 8, 2024 , the Company’s stockholders approved the Amendment at the Company’s 2024 annual meeting of stockholders”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60) at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board adopt a policy requiring the Company’s named executive officers to retain at least 25% of net-after tax shares of stock acquired through equity pay programs until reaching normal retirement age (at least age 60). The proposal received the following votes: Votes For 361,356,676 Votes Against 645,764,310 Abstentions 2,044,338 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company m at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board issue a report detailing the risks and costs to the Company caused by opposing or otherwise altering Company policy in response to state policies regulating abortion, and detailing any strategies beyond litigation and legal compliance that the Company may deploy to minimize or mitigate these risks. The proposal received the following votes: Votes For 17,930,954 Votes Against 977,168,730 Abstentions 14,065,640 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting that the Board include one member from the Company’s non-management employees at the 2024-05-08 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting that the Board include one member from the Company’s non-management employees. The proposal received the following votes: Votes For 59,235,065 Votes Against 946,161,838 Abstentions 3,768,421 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Amendment to the Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation at the 2024-05-08 meeting.

“The Company’s stockholders approved an amendment to the Company’s Restated Certificate of Incorporation to reflect new Delaware law provisions regarding officer exculpation. The proposal received the following votes: Vote For 905,468,022 Vote Against 101,692,634 Abstentions 2,004,668 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Advisory approval of compensation of named executive officers as presented in the Proxy Statement at the 2024-05-08 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: Votes For 928,702,915 Votes Against 78,647,808 Abstentions 1,814,601 Broker Non-Votes 106,243,270”

GILEAD SCIENCES, INC. shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-08 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal received the following votes: Votes For 1,039,381,050 Votes Against 74,100,517 Abstentions 1,927,027”

GILEAD SCIENCES, INC. shareholders approved Election of nine directors to serve for the next year and until their successors are elected and qualified at the 2024-05-08 meeting.

“The Company’s stockholders elected nine directors to serve for the next year and until their successors are elected and qualified. The votes regarding the election of directors were as follows: Name Votes For Votes Against Abstentions Broker Non-Votes Jacqueline K. Barton, Ph.D. 995,391,975 12,399,781 1,373,568 106,243,270 Jeffrey A. Bluestone, Ph.D. 1,000,314,606 7,419,797 1,430,921 106,243,270 Sandra J. Horning, M.D. 985,486,994 22,304,826 1,373,504 106,243,270 Kelly A. Kramer 980,895,123 26,851,069 1,419,132 106,243,270 Ted W. Love, M.D. 1,002,644,132 5,021,345 1,499,847 106,243,270 Harish Manwani 968,115,418 39,518,665 1,531,241 106,243,270 Daniel P. O’Day 939,111,309 63,134,940 6,919,075 106,243,270 Javier J. Rodriguez 1,000,194,729 7,506,046 1,464,549 106,243,270 Anthony Welters 932,173,164 75,508,127 1,484,033 106,243,270”

GILEAD SCIENCES, INC. reported the quarter ended March 31, 2024 results: revenue $6.7 billion, EPS $(3.34).

“providing updates on this and our broad Oncology portfolio throughout the rest of 2024.” First Quarter 2024 Financial Results • Total first quarter 2024 revenue increased 5% to $6.7 billion, compared to the same period in 2023, primarily due to higher HIV, Oncology and Liver Disease sales. • Diluted (loss) earnings per share (“EPS”) was $(3.34) in the first quarter”

Kevin E. Lofton retired as Director at GILEAD SCIENCES, INC..

“On March 10, 2024, Kevin E. Lofton notified the Board of Directors (the “Board”) of Gilead Sciences, Inc., a Delaware corporation (the “Company”), of his decision to retire from the Board, effective as of the conclusion of his term at the Company’s next annual meeting of stockholders to be held on May 8, 2024.”

GILEAD SCIENCES, INC. entered into Agreement and Plan of Merger with CymaBay Therapeutics, Inc. valued at $32.50 per Share (effective 2024-02-11).

“On February 11, 2024, Gilead Sciences, Inc., a Delaware corporation (" Parent " or " Gilead "), entered into an Agreement and Plan of Merger (the " Merger Agreement "), among Parent, CymaBay Therapeutics, Inc., a Delaware corporation (the " Company "), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (" Purchaser ").”

GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2023.

“On February 6, 2024 , Gilead Sciences, Inc., a Delaware corporation ("Gilead"), issued a press release announcing its financial results for the quarter and year ended December 31, 2023.”

Ted W. Love, M.D. was elected as Director at GILEAD SCIENCES, INC..

“the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting.”

GILEAD SCIENCES, INC. reported the third quarter of 2023 results: revenue $7.1 billion, EPS $1.73.

“Total third quarter 2023 revenue of $7.1 billion was flat compared to the same period in 2022, primarily driven by increased sales in Oncology and HIV, offset by lower Veklury”

GILEAD SCIENCES, INC. incurred senior notes of $1,000,000,000 aggregate principal amount of the Company's 5.250% Senior Notes due 2033 and $1,000,000,000 aggregate pri with Computershare Trust Company, National Association at 5.250% per annum on the 2033 Notes and 5.550% per annum on the 2053 Notes maturing October 15, 2033 for the 2033 Notes and October 15, 2053 for the 2053 Notes.

“The Ninth Supplemental Indenture relates to the Company's issuance of (a) $1,000,000,000 aggregate principal amount of the Company's 5.250% Senior Notes due 2033 (the "2033 Notes") and (b) $1,000,000,000 aggregate principal amount of the Company's 5.550% Senior Notes due 2053 (the "2053 Notes" and, together with the 2033 Notes, the "Notes").”

GILEAD SCIENCES, INC. entered into Ninth Supplemental Indenture with Computershare Trust Company, National Association valued at $1,000,000,000 aggregate principal amount of the Company's 5.250% Senior Notes due 2033 and $1,000,0 (effective 2023-09-14).

“On September 14, 2023, Gilead Sciences, Inc. (the “Company”) and Computershare Trust Company, National Association, as successor to Wells Fargo Bank, National Association, as trustee (the “Trustee” and, together with the Company, the “Parties”), entered into a Ninth Supplemental Indenture (the “Ninth Supplemental Indenture”) to the Indenture between the Parties, dated as of March 30, 2011 (the “Base Indenture”).”

GILEAD SCIENCES, INC. reported the quarter ended June 30, 2023 results: revenue $6.6 billion, EPS $0.83 per share (GAAP diluted).

“Total second quarter 2023 revenue increased 5% to $6.6 billion compared to the same period in 2022”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents at the 2023-05-03 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting a report on a process by which the impact of extended patent exclusivities on product access would be considered in deciding whether to apply for secondary and tertiary patents. The proposal received the following votes: Votes For 165,422,837 Votes Against 824,383,326 Abstentions 12,102,240 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting at the 2023-05-03 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting the Board amend the company governing documents to give street name shares and non-street name shares an equal right to call a special stockholder meeting. The proposal received the following votes: Votes For 46,426,089 Votes Against 940,591,356 Abstentions 14,890,958 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders rejected Stockholder proposal requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected at the 2023-05-03 meeting.

“The Company’s stockholders did not approve a stockholder proposal requesting the Board implement a process to nominate at least one more candidate than the number of directors to be elected. The proposal received the following votes: Votes For 7,422,311 Votes Against 982,909,852 Abstentions 11,576,240 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders approved Approval of amendment and restatement of Employee Stock Purchase Plan and International Employee Stock Purchase Plan at the 2023-05-03 meeting.

“The Company’s stockholders approved an amendment and restatement of the Gilead Sciences, Inc. Employee Stock Purchase Plan and the Gilead Sciences, Inc. International Employee Stock Purchase Plan. The proposal received the following votes: Votes For 996,900,619 Votes Against 3,074,231 Abstentions 1,933,553 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders approved Advisory vote on frequency of future advisory stockholder votes on executive compensation at the 2023-05-03 meeting.

“The Company’s stockholders voted, on an advisory basis, on the frequency of future advisory stockholder votes on executive compensation. The frequency receiving the most votes was 1 Year. The proposal received the following votes: 1 Year 985,408,193 2 Years 947,804 3 Years 14,113,020 Abstentions 1,439,386 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders approved Advisory vote on compensation of Named Executive Officers at the 2023-05-03 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s Named Executive Officers as presented in the Proxy Statement. The proposal received the following votes: Votes For 919,145,382 Votes Against 79,500,105 Abstentions 3,262,916 Broker Non-Votes 110,490,647”

GILEAD SCIENCES, INC. shareholders approved Ratification of selection of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-03 meeting.

“The Company’s stockholders ratified the selection of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The proposal received the following votes: Votes For 1,047,348,600 Votes Against 63,802,874 Abstentions 1,247,576”

GILEAD SCIENCES, INC. shareholders approved Election of nine directors at the 2023-05-03 meeting.

“The votes regarding the election of directors were as follows: Name Votes For Votes Against Abstentions Broker Non-Votes Jacqueline K. Barton, Ph.D. 986,415,013 13,491,911 2,001,479 110,490,647 Jeffrey A. Bluestone, Ph.D. 995,919,933 3,943,946 2,044,524 110,490,647 Sandra J. Horning, M.D. 981,121,155 18,770,573 2,016,675 110,490,647 Kelly A. Kramer 966,965,833 32,909,136 2,033,434 110,490,647 Kevin E. Lofton 925,933,861 73,885,649 2,088,893 110,490,647 Harish Manwani 959,762,789 40,053,322 2,092,292 110,490,647 Daniel P. O’Day 923,236,835 70,663,044 8,008,564 110,490,647 Javier J. Rodriguez 993,470,838 6,361,800 2,075,765 110,490,647 Anthony Welters 952,610,095 44,579,806 4,718,502 110,490,647”

GILEAD SCIENCES, INC. reported first quarter of 2023 results: EPS Non-GAAP diluted EPS decreased to $1.37 for the first quarter of 2023 compared to $2.12 for the same period in 2022.

“Total first quarter 2023 revenue decreased 4% to $6.4 billion compared to the same period in 2022, due to lower Veklury® (remdesivir) sales, partially offset by increased sales in HIV and Oncology.”

GILEAD SCIENCES, INC.: Reduced ownership threshold for calling special meeting from 20% to 15% (effective 2023-02-06).

“Effective February 6, 2023, the Board of Directors (the “Board”) of Gilead Sciences, Inc., a Delaware corporation (the “Company”), adopted Amended and Restated Bylaws to reduce the ownership threshold required to call a special meeting of stockholders to provide that one or more stockholders owning in the aggregate not less than fifteen percent (15%) of the Company’s outstanding common stock shall have the right to call a special meeting.”

GILEAD SCIENCES, INC. reported financial results for the quarter and year ended December 31, 2022.

“On February 2, 2023 , Gilead Sciences, Inc., a Delaware corporation (“Gilead”), issued a press release announcing its financial results for the quarter and year ended December 31, 2022.”

Sandra Patterson was named as Senior Vice President, Corporate Controller, and principal accounting officer at GILEAD SCIENCES, INC..

“The Company has named Sandra Patterson, who currently serves as Vice President, Assistant Controller, to be the Company’s Senior Vice President, Corporate Controller, and principal accounting officer, effective March 1, 2023”

Diane Wilfong departed as Senior Vice President, Corporate Controller and Chief Accounting Officer at GILEAD SCIENCES, INC..

“announced that Diane Wilfong plans to step down from her positions as the Company’s Senior Vice President, Corporate Controller and Chief Accounting Officer effective March 1, 2023”

Brett A. Pletcher retired as Executive Vice President, Corporate Affairs and General Counsel at GILEAD SCIENCES, INC..

“In connection with the previously announced plans for Brett A. Pletcher to retire as the Company’s Executive Vice President, Corporate Affairs and General Counsel, the Compensation and Talent Committee of the Board of Directors of Gilead Sciences, Inc., a Delaware corporation (the “Company”), on May 25, 2022, approved compensation terms for Mr. Pletcher to serve in a part-time capacity following such retirement”

Brett A. Pletcher departed as Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary at GILEAD SCIENCES, INC..

“On January 6, 2022, Gilead Sciences, Inc., a Delaware corporation (the “Company”), announced that Brett A. Pletcher plans to retire from his position as the Company’s Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary.”